FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Denies Apixaban ANDA Petition for Safety

[ Price : $8.95]

FDA denies for reasons of safety a 2017 petition seeking approval to submit an ANDA for a generic form of Bristol-Myers Squibbs El...

SCA Pharma Issued 10-Item FDA-483

[ Price : $8.95]

FDA posts a 10-item Form FDA-483 related to an inspection last month at SCA Pharmaceuticals Windsor, CT outsourcing facility.

AdvaMed Comments on Electronic Submission Guide

[ Price : $8.95]

AdvaMed raises concerns about an FDA draft guidance on De Novo electronic submissions.

Concerns About FDA QMM Program

[ Price : $8.95]

The Association for Accessible Medicines raises several issues and concerns with FDAs proposal to develop a quality management mat...

Durbin, Grassley Push Drug Ad Transparency Bill

[ Price : $8.95]

Sen. Mike Crapo blocks an attempt by Sens. Dick Durbin and Charles Grassley to get unanimous consent to approve their bipartisan d...

Regenerative Medicine Consensus Standards Guide

[ Price : $8.95]

FDA publishes a guidance describing CBERs standards recognition program for regenerative medicine therapies.

Similar Intas CGMP Violations

[ Price : $8.95]

FDA warns Intas Pharmaceuticals about repeat CGMP violations at its drug manufacturing facility in Matoda-Sanand, Ahmedabad, India...

Korsuva Regulatory Review Period

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Cara Therapeutics Korsuva (...

Cosela Regulatory Review Period

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for G1 Therapeutics Cosela (tr...

Info Collection on Device Shortages Data

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection extension entitled Shortages Data Collections.